HRP20050679A2 - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents

Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Info

Publication number
HRP20050679A2
HRP20050679A2 HR20050679A HRP20050679A HRP20050679A2 HR P20050679 A2 HRP20050679 A2 HR P20050679A2 HR 20050679 A HR20050679 A HR 20050679A HR P20050679 A HRP20050679 A HR P20050679A HR P20050679 A2 HRP20050679 A2 HR P20050679A2
Authority
HR
Croatia
Prior art keywords
denotes
nr5r6
cycloalkyl
alkyl
alkenyl
Prior art date
Application number
HR20050679A
Other languages
English (en)
Inventor
Patek Marcel
Nair Anil
Hittinger Augustin
Nemecek Conception
Bond Daniel
Harlow Greg
Bouchard Herv
Mauger Jacques
Malleron Jean-Luc
Palermo Mark
Al-Obeidi Fahad
Faitg Thomas
Ruf Sven
Ritter Kurt
El-Ahmad Youssef
Lesuisse Dominique
Strobel Hartmut
Benard Didier
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20050679A2 publication Critical patent/HRP20050679A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Izum se odnosi na nove produkte koji imaju formulu (I), u kojoj: primjer označava 0 do 2, Radikal iR1 označavaju 0 ili NH; R2 i R3 označavaju vodik,alkil, alkenil, alkinil, cikloalkil, aril ili heteroaril, ili R2 i R3, zajedno s atomom ugljika na kojeg su vezani, tvore karbociklički ili heterociklički radikal, svi od navedenih radikala su po izboru supstituirani; A1 označava jednostruku vezu, alkil, alil ili propinil; Y i Y1 označavaju vodik, OCF3, S(O)nCF3, S(O)Alk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 i SO2NR5NR6, gdjesu R5 i R6 izabrani između vodika, alkil, alkenil, cikloalkil, cikloalkenil, heterocikloalkil, arili heteroaril, koji su po izboru supstituirani, ili R5 i R6 zajedno s N atomom na kojeg su vezani, tvore heterociklički radikal; A2 označava A1, CO i SO2; B2 označava heterociklički radikal koji je poizboru supstituiran s jednim ili više supstituenta koji su izabrani između mogućnosti od Y2; Y2 označava vodik, halogen, hidroksil, ciano, alkil, alkoksi, cikloalkil, heterocikloalkil, aril, heteroaril, -O-alkenil, -O-alkinil, -O-cikloalkil, S(O)n-alkil, - S(O)n-alkenil, - S(O)n-alkinil, - S(O)n-cikloalkil, -C00R13, NR5R6, CONR5R6, S(O)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, svi od navedenih radikala su po izboru supstituiran; i n označava cijeli broj između 0 i 2. Za uporabu kao medikamenata, ranije spomenuti produkti su u svim izomernim oblicima i soli od njih.
HR20050679A 2003-01-31 2005-07-29 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors HRP20050679A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
HRP20050679A2 true HRP20050679A2 (en) 2006-12-31

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050679A HRP20050679A2 (en) 2003-01-31 2005-07-29 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1599464B1 (hr)
JP (1) JP4604020B2 (hr)
KR (1) KR20050098286A (hr)
CN (1) CN1768054A (hr)
AR (1) AR042936A1 (hr)
AT (1) ATE482207T1 (hr)
AU (1) AU2004209319A1 (hr)
BR (1) BRPI0407091A (hr)
CA (1) CA2513631A1 (hr)
DE (1) DE602004029236D1 (hr)
FR (1) FR2850652B1 (hr)
HR (1) HRP20050679A2 (hr)
MA (1) MA27651A1 (hr)
ME (1) MEP22608A (hr)
MX (1) MXPA05007407A (hr)
NO (1) NO20054006L (hr)
NZ (1) NZ541270A (hr)
PE (1) PE20040808A1 (hr)
PL (1) PL377811A1 (hr)
RS (1) RS20050657A (hr)
RU (1) RU2341523C2 (hr)
TW (1) TW200505898A (hr)
WO (1) WO2004070050A2 (hr)
ZA (1) ZA200505934B (hr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3081214A3 (en) 2003-08-29 2016-11-16 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2299266A1 (en) 2003-12-19 2011-03-23 The Regents of the University of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PT2444085E (pt) 2005-05-13 2015-06-11 Univ California Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
CN102316735A (zh) 2008-12-23 2012-01-11 哈佛大学校长及研究员协会 坏死性凋亡的小分子抑制剂
PT3124481T (pt) 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
AU2011349525B2 (en) * 2010-12-21 2015-05-21 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
GEP20196983B (en) 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018014829A1 (en) * 2016-07-20 2018-01-25 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
EP3705474A4 (en) * 2017-10-31 2021-06-09 Pelemed Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ACUTE MYELOIC LEUKEMIA OR METASTATIC BREAST CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
BR9811260A (pt) * 1997-03-03 2000-08-08 Boehringer Ingelheim Pharma Pequenas moléculas úteis no tratamento de doença inflamatória
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
WO2001092253A2 (en) * 2000-05-31 2001-12-06 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha l beta 2 mediated cell adhesion
JP4623279B2 (ja) * 2002-05-16 2011-02-02 メリアル・リミテッド ピリジンカルボキサミド誘導体および農薬としてのその使用

Also Published As

Publication number Publication date
RS20050657A (en) 2007-06-04
NO20054006L (no) 2005-10-13
JP4604020B2 (ja) 2010-12-22
RU2005127335A (ru) 2006-09-10
PL377811A1 (pl) 2006-02-20
RU2341523C2 (ru) 2008-12-20
CA2513631A1 (fr) 2004-08-19
NO20054006D0 (no) 2005-08-29
ZA200505934B (en) 2007-06-27
MEP22608A (en) 2010-06-10
BRPI0407091A (pt) 2006-01-24
JP2006517569A (ja) 2006-07-27
EP1599464B1 (fr) 2010-09-22
AU2004209319A1 (en) 2004-08-19
EP1599464A2 (fr) 2005-11-30
WO2004070050A2 (fr) 2004-08-19
ATE482207T1 (de) 2010-10-15
WO2004070050A3 (fr) 2005-02-17
KR20050098286A (ko) 2005-10-11
FR2850652B1 (fr) 2008-05-30
CN1768054A (zh) 2006-05-03
NZ541270A (en) 2008-11-28
PE20040808A1 (es) 2004-12-31
AR042936A1 (es) 2005-07-06
MXPA05007407A (es) 2005-09-12
TW200505898A (en) 2005-02-16
DE602004029236D1 (de) 2010-11-04
FR2850652A1 (fr) 2004-08-06
MA27651A1 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
HRP20050679A2 (en) Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20063780L (no) Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
CO5580747A2 (es) Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
NO20063028L (no) 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
AR057979A1 (es) PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
MXPA03010129A (es) N-aroilaminas-ciclicas.
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
ES2333802T3 (es) Inhibidores no nucleicos de transcriptasa inversa.
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
ATE533773T1 (de) Phosphor-haltige heptazinderivate, verfahren zu deren herstellung und deren verwendung als flammschutzmittel
SE0202133D0 (sv) Novel compounds
NO20082975L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
DE60142934D1 (de) Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung
NO20061045L (no) Imidazolderivater
SE0303541D0 (sv) New compounds
MXPA04002495A (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
NO20060079L (no) 6-(1,1-Difluoralkyl)-4-Aminopikolinater og deres anvendelse som Herbicider
AR036812A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090127

Year of fee payment: 6

OBST Application withdrawn